Literature DB >> 8582109

The influence of the renin angiotensin system on abnormal expression of nerve growth factor in the spontaneously hypertensive rat.

S Jeffreson1, R Rush, C Zettler, D B Frewin, R J Head.   

Abstract

1. The levels of the neurotrophic factor, nerve growth factor (NGF) in the mesenteric vascular bed of the spontaneously hypertensive rat (SHR) were greater than those in the corresponding vascular bed of normotensive Wistar-Kyoto rats (WKY). 2. Administration of angiotensin II (200 ng/kg per min, by minipump) for 2 weeks to juvenile WKY rats increased the levels of NGF in the mesenteric vasculature to those seen in untreated SHR. 3. Administration of the angiotensin II receptor antagonists losartan (30 mg/kg per day, p.o.) or PD144277 (10 mg/kg per day, p.o.) to juvenile SHR for 4 weeks reduced the levels of NGF such that they were indistinguishable from the values obtained for normotensive WKY rats. 4. The results confirm the elevated level of NGF in the mesenteric vasculature of the SHR and suggest that angiotensin II may play a role in regulating the abnormal concentrations of the protein in this tissue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582109     DOI: 10.1111/j.1440-1681.1995.tb02050.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

1.  Type-1 angiotensin receptors are expressed and transported in motor and sensory axons of rat sciatic nerves.

Authors:  Hui Tang; Jaroslav Pavel; Juan M Saavedra; Stephen Brimijoin
Journal:  Neuropeptides       Date:  2009-02-23       Impact factor: 3.286

2.  Angiotensin-(1-7) attenuates atrial tachycardia-induced sympathetic nerve remodeling.

Authors:  Wenfeng Shangguan; Wen Shi; Guangping Li; Yuanyuan Wang; Jian Li; Xuewen Wang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2017 Jul-Sep       Impact factor: 1.636

Review 3.  A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19.

Authors:  Jennifer H Martin; Richard Head
Journal:  Br J Clin Pharmacol       Date:  2020-11-18       Impact factor: 3.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.